Treatment of Pediatric Atopic Dermatitis

Basic Therapy (For All Severity Levels)

The American Academy of Pediatrics recommends regular application of fragrance-free emollients to maintain skin barrier integrity in all children with atopic dermatitis 1
Lukewarm baths with gentle, soap-free cleansers followed by emollient application help maintain skin hydration 1
Identification and avoidance of triggers such as allergens, irritants, and environmental factors is crucial for management, as suggested by the Journal of Microbiology, Immunology and Infection 2, 1
Comprehensive education for caregivers about proper skin care improves outcomes, according to the Journal of Microbiology, Immunology and Infection 3

The preferred treatment is reactive therapy with low-potency topical corticosteroids during flares, as recommended by the Journal of Microbiology, Immunology and Infection 3, 1

The preferred treatment is proactive and reactive therapy with low to medium potency topical corticosteroids, according to the Journal of Microbiology, Immunology and Infection 3, 1
Proactive therapy with twice-weekly application of topical corticosteroids or topical calcineurin inhibitors to previously affected areas helps prevent relapses, as suggested by the Journal of Microbiology, Immunology and Infection 2, 3

The preferred treatment is proactive and reactive therapy with medium to high potency topical corticosteroids, as recommended by the Journal of Microbiology, Immunology and Infection 3, 1
Add-on therapies include wet-wrap therapy with topical corticosteroids for short-term use, oral antihistamines for reducing pruritus, and dupilumab for refractory cases, according to the Journal of Microbiology, Immunology and Infection 2, 3

Low-potency topical corticosteroids should be used for sensitive areas and in infants to avoid skin atrophy, as suggested by the American Academy of Pediatrics 1
Long-term application of topical antibiotics is not recommended due to increased risk of resistance and skin sensitization, according to the Journal of Microbiology, Immunology and Infection 2
Systemic corticosteroids should be used only for short periods in severe acute exacerbations due to risk of rebound flares upon discontinuation, as recommended by the Journal of Microbiology, Immunology and Infection 3
Phototherapy is not recommended for children younger than 12 years as long-term safety remains unclear, according to the Journal of Microbiology, Immunology and Infection 2

For patients with severe to very severe atopic dermatitis, the American Academy of Dermatology recommends wet-wrap therapy with topical corticosteroids as an effective short-term second-line treatment for 3-5 days, and dupilumab is the first-line biologic for severe disease not responding to topical treatment 4
The American Academy of Dermatology suggests that for facial, genital, and intertriginous areas, topical calcineurin inhibitors such as tacrolimus 0.1% ointment are effective as first-line therapy to avoid skin atrophy, with studies showing clearance within 2 weeks in pediatric facial psoriasis and similar efficacy expected in atopic dermatitis 5

The American Academy of Dermatology advises against the use of high-potency or ultra-high-potency topical corticosteroids in children due to increased risk of hypothalamic-pituitary-adrenal axis suppression, particularly in those with high body surface area involvement, and recommends careful instruction on amount to apply and safe sites for use 5
The Journal of Microbiology, Immunology and Infection recommends avoiding long-term topical antibiotics due to increased resistance and sensitization risk, and not using topical antihistamines due to insufficient evidence for efficacy and increased risk of contact dermatitis 4

The American Academy of Dermatology recommends not using systemic corticosteroids for maintenance due to rebound flares upon discontinuation, reserving them only for short-term crisis management, and not recommending phototherapy for children under 12 years as long-term safety remains unclear 4
The American Academy of Dermatology advises against abruptly discontinuing high-potency corticosteroids without transitioning to appropriate alternative treatment to avoid rebound flares 5

The Journal of Microbiology, Immunology and Infection reports that crisaborole, a topical PDE-4 inhibitor, is approved for mild to moderate atopic dermatitis in patients 3 months and older, serving as an alternative to topical corticosteroids or calcineurin inhibitors 4